Progress in acute graft versus host disease

Current Opinion in Hematology

Volumn 14, Issue 6, 2007, Pages 625-631

  Holler, Ernst ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

Acute GvHD; Antigen presenting cells; Cytokines; Regulatory T cells

Indexed keywords

BECLOMETASONE; OKT 3; PALIFERMIN; REPIFERMIN;

ACUTE GRAFT VERSUS HOST DISEASE; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; CELL FUNCTION; CLINICAL FEATURE; CLINICAL STUDY; CLINICAL TRIAL; DRUG DOSE ESCALATION; EFFECTOR CELL; EXPERIMENTAL STUDY; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RISK FACTOR;

ACUTE DISEASE; ANTIGEN-PRESENTING CELLS; CYTOKINES; GRAFT VS HOST DISEASE; HUMANS; T-LYMPHOCYTES;

EID: 34848915188     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3282f08dd9     Document Type: Review

References (55)

1. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11:945-956.
2. Durakovic N, Bezak KB, Skarica M, et al. Host-derived Langerhans cells persist after MHC-matched allografting independent of donor T cells and critically influence the alloresponses mediated by donor lymphocyte infusions. J Immunol 2006; 177:4414-4425. This elegant experimental study demonstrated that host Langerhans cells persist in cutaneous lymph nodes in MHC matched BMT whereas mismatched BMT results in rapid donor cell chimerism. Application of imiquimod, a TLR7 agonist, induced a lymphohaematopoietic GvH reaction and faster replacement by donor cells.
3. Hirshfeld E, Weiss L, Kasir J, et al. Post transplant persistence of host cells augments the intensity of acute graft-versus-host disease and level of donor chimerism: An explanation for graft-versus-host disease and rapid displacement of host cells seen following nonmyeloablative stem cell transplantation? Bone Marrow Transplant 2006; 38:359-364. This study mimicked the effect of persistence of host APCs by additional infusion of host cells following BMT.
4. Collin MP, Hart DN, Jackson GH, et al. The fate of human Langerhans cells in hematopoietic stem cell transplantation. J Exp Med 2006; 203:27-33. Using confocal microscopy of skin Langerhans cells and chimerism analysis in Langerhans cells migrating from punch biopsies this elegant study reported more rapid exchange of Langerhans cells in patients receiving full intensity conditioning. Prior acute skin GvHD significantly promoted development of full donor chimerism.
5. Auffermann-Gretzinger S, Eger L, Bornhauser M, et al. Fast appearance of donor dendritic cells in human skin: dynamics of skin and blood dendritic cells after allogeneic hematopoietic cell transplantation. Transplantation 2006; 81:866-873. By assessing chimerism of Langerhans cells and dermal dendritic cells emigrating from human shave biopsies rapid donor chimerism of dendritic cells was observed which was not affected by the intensity of conditioning.
6. Auffermann-Gretzinger S, Eger L, Schetelig J, et al. Alemtuzumab depletes dendritic cells more effectively in blood than in skin: a pilot study in patients with chronic lymphocytic leukemia. Transplantation 2007; 83:1268-1272.
7. Lau J, Sartor M, Bradstock KF, et al. Activated circulating dendritic cells after hematopoietic stem cell transplantation predict acute graft-versus-host disease. Transplantation 2007; 83:839-846. The CMRF-44 antibody detects an activation antigen on human circulating myeloid dendritic cells, and its expression correlates with the presence of GvHD.
8. Yuksel M, Baron E, Camouse M, et al. Peritransplant use of ultraviolet-B irradiation (UV-B) therapy is detrimental to allogeneic stem cell transplantation outcome. Biol Blood Marrow Transplant 2006; 12:665-671.
9. Chakraverty R, Cote D, Buchli J, et al. An inflammatory checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral tissues. J Exp Med 2006; 203:2021-2031. This is a fascinating analysis of the role of activation of APCs in target tissues for the invasion of donor T cells in GvHD. Irradiation of hosts and local activation with TLR agonists are prerequisites for establishment of GvHD.
10. Tschopp J, Martinon F, Burns K. NALPs: a novel protein family involved in inflammation. Nat Rev Mol Cell Biol 2003; 4:95-104.
11. Holler E, Rogler G, Brenmoehl J, et al. Prognostic significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem cell transplantation: effect on long-term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination. Blood 2006; 107:4189-4193. The prognostic significance of NOD2/CARD15 SNPs was analysed and confirmed in two sequential cohorts of HLA identical sibling transplants.
12. Elmaagacli AH, Koldehoff M, Hindahl H, et al. Mutations in innate immune system NOD2/CARD 15 and TLR-4 (Thr399Ile) genes influence the risk for severe acute graft-versus-host disease in patients who underwent an allogeneic transplantation. Transplantation 2006; 81:247-254.
13. Granell M, Urbano-Ispizua A, Arostegui JI, et al. Effect of NOD2/CARD15 variants in T-cell depleted allogeneic stemcell transplantation. Haematologica 2006; 91:1372-1376.
14. Chien JW, Zhao LP, Hansen JA, et al. Genetic variation in bactericidal/permeability-increasing protein influences the risk of developing rapid airflow decline after hematopoietic cell transplantation. Blood 2006; 107:2200-2207.
15. Rowe V, Banovic T, MacDonald KP, et al. Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation. Blood 2006; 108:2485-2492. Using knockout mice for IL10, this group elegantly demonstrated the role of host B cells in dampening the activation of donor T cell alloresponses.
16. She K, Gilman AL, Aslanian S, et al. Altered Toll-like receptor 9 responses in circulating B cells at the onset of extensive chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007; 13:386-397.
17. Cutler C, Miklos D, Kim HT, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006; 108:756-762.
18. Asavaroengchai W, Wang H, Wang S, et al. An essential role for IFN-gamma in regulation of alloreactive CD8 T cells following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007; 13:46-55. IFNγ knockout donors showed accelerated cell division and reduced activation induced cell death of donor CD8 cells which translated in more severe GvHD. This paper challenges the common view on IFNγ as a major effector cytokine worsening GvHD.
19. Burman AC, Banovic TD, Kuns RD, Clouston AD, Stanley AC, Morris ES. IFNγ differentially controls the development of idiopathic pneumonia syndrome and GVHD of the gastrointestinal tract. Blood 2007; 110:1064-1072. In this excellent paper, the role of IFNγ is further clarified. By using IFNγ-receptor knockouts authors clarify that host cells are critically activated by donor IFNγ in GvHD, but not further donor T cells. They show that excess mortality due to IFNγ is mediated by increased pulmonary damage and suggest that IFNγ downregulates adhesion molecules allowing cellular infiltration of the lung.
20. Chen BJ, Deoliveira D, Cui X, et al. Inability of memory T cells to induce graft-versus-host disease is a result of an abortive alloresponse. Blood 2007; 109:3115-3123.
21. Gorski J, Chen X, Gendelman M, Yassai M, Krueger A, Tivol E. Homeostatic expansion and repertoire regeneration of donor T cells during graft versus host disease is constrained by the host environment. Blood 2007; 109:5502-5510. In this paper, the authors address the generation of lymphopenia in GvHD and show that this is not due to an intrinsic defect in GvHD reactive T cells but due to altered interaction of the damaged host environment with donor T cells.
22. Mapara MY, Leng C, Kim YM, et al. Expression of chemokines in GVHD target organs is influenced by conditioning and genetic factors and amplified by GVHR. Biol Blood Marrow Transplant 2006; 12:623-634. In this clinical study, circulating CCR10+CD4+ cells producing Th1 type cytokines were correlated with skin GvHD. They were detected in specific cellular infiltrates in skin biopsies where also the relevant ligand CCL27/CTACK was upregulated in epidermal cells.
23. Faaij CM, Lankester AC, Spierings E, et al. A possible role for CCL27/CTACK-CCR10 interaction in recruiting CD4 T cells to skin in human graft-versus-host disease. Br J Haematol 2006; 133:538-549.
24. Avanzini MA, Maccario R, Locatelli F, et al. Low percentages of circulating CD8(+)/CD45RA(+) human T lymphocytes expressing beta7 integrin correlate with the occurrence of intestinal acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Exp Hematol 2006; 34:1429-1434.
25. Waldman E, Lu SX, Hubbard VM, et al. Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine. Blood 2006; 107:1703-1711. Donor cells lacking the β7 integrin were able to mount a normal alloresponse in vitro but resulted in reduced intestinal and hepatic GvHD. This study strongly supports the concept of a major role of appropriate homing of donor cells to target organs of GvHD.
26. Ueha S, Murai M, Yoneyama H, et al. Intervention of MAdCAM-1 or fractalkine alleviates graft-versus-host reaction associated intestinal injury while preserving graft-versus-tumor effects. J Leukoc Biol 2007; 81:176-185. Further proof of the concept of homing is presented in this paper as the authors were able to prevent severe GvHD by monoclonal antibodies blocking the ligands for α4β7 integrins.
27. Welniak LA, Kuprash DV, Tumanov AV, et al. Peyer patches are not required for acute graft-versus-host disease after myeloablative conditioning and murine allogeneic bone marrow transplantation. Blood 2006; 107:410-412. In a myeloablative transplant model, the central role of Peyer's patches for T cell homing may be overcome, as TNF receptor 1 knockout mice lacking Peyer's patches still developed severe GvHD.
28. Yamazaki S, Patel M, Harper A, et al. Effective expansion of alloantigen-specific Foxp3+ CD25+ CD4+ regulatory T cells by dendritic cells during the mixed leukocyte reaction. Proc Natl Acad Sci USA 2006; 103:2758-2763. Authors used both in-vitro MLRs and models of GvHD induction to demonstrate the superiority of mature dendritic cells in expanding alloantigen specific T regs. Only dendritic cell expanded T regs were able to suppress MLR and GvHD while T regs expanded by splenic cells as stimulators exhibited no or weak protection.
29. Tang Q, Bluestone JA. Plasmacytoid DCs and T(reg) cells: casual acquaintance or monogamous relationship? Nat Immunol 2006; 7:551-553. This review summarizes the current concept of how regulatory T cells interact with dendritic cell subtypes to maintain a tailored immune response.
30. Zeiser R, Nguyen VH, Hou JZ, et al. Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease. Blood 2007; 109:2225-2233. This paper characterizes the role of the CD30/CD153 pathway in GvHD protection by regulatory T cells.
31. Nguyen VH, Zeiser R, Dasilva DL, et al. In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation. Blood 2007; 109:2649-2656. The Stanford group used the bio-imaging approach to define the conditions required for expansion of allo-antigen specific T regs. Both, presence of allo-antigen and inflammatory signals mediated by total body irradiation were prerequisites for T reg expansion. At early timepoints after BMT, lower numbers of T regs were sufficient to suppress GvHD, while after expansion of conventional T cells higher number of T regs induced only partial protection.
32. MacDonald KP, Kuns RD, Rowe V, et al. Effector and regulatory T-cell function is differentially regulated by RelB within antigen-presenting cells during GVHD. Blood 2007; 109:5049-5057.
33. Trenado A, Sudres M, Tang Q, et al. Ex vivo-expanded CD4+CD25+ immunoregulatory T cells prevent graft-versus-host-disease by inhibiting activation/differentiation of pathogenic T cells. J Immunol 2006; 176:1266-1273.
34. Mutis T, van Rijn RS, Simonetti ER, et al. Human regulatory T cells control xenogeneic graft-versus-host disease induced by autologous T cells in RAG2-/-gammac-/- immunodeficient mice. Clin Cancer Res 2006; 12:5520-5525. In the RAG2-/- common γ chain (γc)-/- mouse, xenogenic GvHD induced by CD4 and CD8 cells is prevented by naturally occurring T regs. Interestingly, the protected mice produced increased level of both, IL10 and IFNγ after 3 weeks suggesting additional involvement of TR1 regulatory cells.
35. Kleinclauss F, Perruche S, Masson E, et al. Intravenous apoptotic spleen cell infusion induces a TGF-beta-dependent regulatory T-cell expansion. Cell Death Differ 2006; 13:41-52. Infusion of apoptotic spleen cells prevents GvHD by host-macrophage, not dendritic cell dependent induction of T regs.
36. Rieger K, Loddenkemper C, Maul J, et al. Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD. Blood 2006; 107:1717-1723. This elegant study addressed for the first time the distribution of Tregs in GvHD target tissues. The number of T regs in relation to 100 CD8 cells were quite low in gastrointestinal biopsies from patients with acute and chronic GvHD, but high in patients with CMV colitis and diverticulitis.
37. Pabst C, Schirutschke H, Ehninger G, et al. The graft content of donor T cells expressing γδ TCR+ and CD4+foxp3+ predicts the risk of acute graft versus host disease after transplantation of allogeneic peripheral blood stem cells from unrelated donors. Clin Cancer Res 2007; 13:2916-2922.
38. Rezvani K, Mielke S, Ahmadzadeh M, et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 2006; 108:1291-1297. By comparing donor Tregs and T regs in patients early after SCT, this paper describes and inverse relation between T regs and occurrence of acute GvHD.
39. Hoffmann P, Boeld TJ, Eder R, et al. Isolation of CD4+CD25+ regulatory T cells for clinical trials. Biol Blood Marrow Transplant 2006; 12:267-274.
40. Pillai AB, George TI, Dutt S, et al. Host NKT cells can prevent graft-versus-host disease and permit graft antitumor activity after bone marrow transplantation. J Immunol 2007; 178:6242-6251. This murine study provided a further basis for the GvHD protection by the total lymphoid irradiation/ antilymphocytes serum approach as hosts deficient for NKT cells (CD1d-/-) were not protected from GvHD.
41. McQueen KL, Dorighi KM, Guethlein LA, et al. Donor-recipient combinations of group A and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched, sibling donor hematopoietic cell transplantation. Hum Immunol 2007; 68:309-323. The group of Parham used PCR based KIR typing to determine recipient and donor KIR haplotypes in HLA-identical sibling transplantation: The recipient AA and donor Bx group had significantly poorer survival in patients with myeloid leukaemia, which was mainly due to lower disease free survival but also some increase in GvHD.
42. Murphy N, Diviney M, Szer J, et al. Donor methylenetetrahydrofolate reductase genotype is associated with graft-versus-host disease in hematopoietic stem cell transplant patients treated with methotrexate. Bone Marrow Transplant 2006; 37:773-779.
43. Robien K, Bigler J, Yasui Y, et al. Methylenetetrahydrofolate reductase and thymidylate synthase genotypes and risk of acute graft-versus-host disease following hematopoietic cell transplantation for chronic myelogenous leukemia. Biol Blood Marrow Transplant 2006; 12:973-980.
44. Tamouza R, Busson M, Rocha V, et al. Homozygous status for HLA-E*0103 confers protection from acute graft-versus-host disease and transplant-related mortality in HLA-matched sibling hematopoietic stem cell transplantation. Transplantation 2006; 82:1436-1440. The Paris group now applied HLA-E genotyping to recipients and donors following HLA-identical sibling SCT and report protection by homozygosity for HLSA-E*0103.
45. Saliba RM, de Lima M, Giralt S, et al. Hyperacute GVHD: risk factors, outcomes, and clinical implications. Blood 2007; 109:2751-2758. More than 20% of patients with GvHD develop hyperacute GvHD before day 14 in this large series of patients, and occurrence of hyperacute GvHD was associated with high nonrelapse mortality.
46. Leisenring WM, Martin PJ, Petersdorf EW, et al. An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. Blood 2006; 108:749-755. In this manuscript, implementation of simple clinical parameters helped to establish a clinical GvHD severity index, which allowed time-dependent prediction of day 200 mortality. This index may be helpful to identify patients who should receive more aggressive treatment of GvHD using investigational protocols.
47. Weissinger EM, Schiffer E, Hertenstein B, Ferrara JL, Holler E, Stadler M. Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2007; 109:5511-5519. This confirmatory study demonstrated that urine anylsis by proteomics identifies peptides which may predict occurrence of GvHD. This approach needs now validation in prospective studies on early or even preemptive treatment of GvHD.
48. Clouthier SG, Cooke KR, Teshima T, et al. Repifermin (keratinocyte growth factor-2) reduces the severity of graft-versus-host disease while preserving a graft-versus-leukemia effect. Biol Blood Marrow Transplant 2003; 9:592-603.
49. Blazar BR, Weisdorf DJ, Defor T, et al. Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood 2006; 108:3216-3222. In spite of reduction of mucositis after CY/TBI regimens, the prophylactic application of keratinocyte growth factor did not reduce acute GvHD.
50. Bacigalupo A, Lamparelli T, Barisione G, et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006; 12:560-565.
51. van Lint MT, Milone G, Leotta S, et al. Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving antithymocyte globulin. Blood 2006; 107:4177-4181. This is an important and consequent study demonstrating clearly the prognostic significance of early response to first line treatment of GvHD. Even after only more than 5 days of treatment, addition of antithymocyte globuline failed to improve survival, mainly due to the increased risk of infection.
52. Hockenbery DM, Cruickshank S, Rodell TC, et al. A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood 2007; 109:4557-4563. This study may change clinical practice as early addition of beclomethasone reduced the risk of treatment failure of gastrointestinal GvHD. Even more important, a clear survival advantage at day 200 is seen which can be attributed to the reduction of use of systemic corticosteroids.
53. MacMillan ML, Couriel D, Weisdorf DJ, et al. A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood 2007; 109:2657-2662.
54. Knop S, Hebart H, Gratwohl A, Kliem C, Faul C, Holler E. Treatment of steroid-resistant acute GVHD with OKT3 and high-dose steroids results in better disease control and lower incidence of infectious complications when compared to high-dose steroids alone: a randomized multicenter trial by the EBMT Chronic Leukemia Working Party. Leukemia 2007; 21:1830-1833. This study was limited by the small number of patients but suggested that T cell depletion as induced by OKT3 may be an option in steroid refractory GvHD as OKT3 gave a clear trend for a better response rate and a better survival at 1 year.
55. Ringden O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006; 81:1390-1397. The first example of an alternative approach using cellular therapy is reported in this elegant study. The authors confirm their previous success to rescue patients with refractory GvHD by the infusion of mesenchymal stem cells.